1 / 4

BRAVER Trial

BR achial A rtery V ascular E ndothelium R eactivity Study A substudy of PROVE IT-TIMI 22. BRAVER Trial. BRAVER: Study design. Substudy of PROVE IT-TIMI 22. Objective: – Evaluate time course of improvement in endothelial function with statin after acute coronary syndromes (ACS)

brownjamie
Download Presentation

BRAVER Trial

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. BRachial Artery Vascular Endothelium Reactivity Study A substudy of PROVE IT-TIMI 22 BRAVER Trial

  2. BRAVER: Study design Substudy of PROVE IT-TIMI 22 Objective: – Evaluate time course of improvement in endothelial function with statin after acute coronary syndromes (ACS) – Compare effects of intense vs moderate statin therapies on vascular reactivity Design: Randomized double-blind 2 x 2 factorial design Population: N = 50 with ACS; total cholesterol ≤240 mg/dL* Treatment: Atorvastatin 80 mg (n = 24) or pravastatin 40 mg (n = 26) Outcome: Amount of change in brachial artery reactivity measured by high-resolution ultrasound at days 2, 30, and 120 *≤200 mg/dL if on long-term lipid-lowering drugs BRachial Artery Vascular Endothelium Reactivity Dupuis J et al. Am J Cardiol. 2005;96:1207-13.

  3. BRAVER: Results • 32% reduction in LDL-C with atorvastatin 80 mg (P < 0.001 vs baseline) vs no reduction with pravastatin 40 mg after 4 months • Similar reductions in C-reactive protein (CRP) in both treatment groups • 27% increase in FMD; 24% increase in NMD (P <0.05 vs baseline), with no difference between treatment strategies • Changes in FMD, lipid levels, and CRP were not correlated • FMD and NMD remained unchanged in patients treated with statins prior to ACS (n = 15) FMD = Endothelium-dependent flow-mediated dilation NMD = Endothelium-independent sublingual nitroglycerin-mediated dilation BRachial Artery Vascular Endothelium Reactivity Dupuis J et al. Am J Cardiol. 2005;96:1207-13.

  4. BRAVER: Clinical implications • Statin therapy soon after ACS improves endothelium-dependent and endothelium-independent vascular reactivity • Improvements observed after 4 months of treatment • Results comparable despite differing intensities of treatment • Power to detect differences between atorvastatin and pravastatin groups was limited; findings add to growing evidence that improvement in vascular reactivity with statins is independent of the importance of lowering cholesterol • Lack of improvement in subjects previously using statins suggests new statin initiation is needed for major improvements in vascular reactivity after ACS BRachial Artery Vascular Endothelium Reactivity Dupuis J et al. Am J Cardiol. 2005;96:1207-13.

More Related